American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 
MENLO PARK, Calif., Feb. 26, 2018 -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, announced today that Amber Salzman, Ph.D., president and chief executive officer of Adverum, will present at upcoming investor conferences in March.
| Event: | Raymond James 39th Annual Institutional Investors Conference | ||||
| Date: | March 5, 2018 | ||||
| Time: | 9:15 – 9:45 a.m. ET | ||||
| Location: | Orlando, FL | ||||
| Event: | Cowen and Company 38th Annual Health Care Conference | ||||
| Date: | March 12, 2018 | ||||
| Time: | 1:30 – 2:00 p.m. ET | ||||
| Location: | Boston, MA | ||||
| |
A live and replay audio webcast of these presentations will be available from Adverum’s website at http://investors.adverum.com.
About Adverum Biotechnologies, Inc.
Adverum is a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases. Adverum has a robust pipeline that includes product candidates designed to treat rare diseases alpha-1 antitrypsin (A1AT) deficiency and hereditary angioedema (HAE) as well as wet age-related macular degeneration (wAMD). Leveraging a next-generation adeno-associated virus (AAV)-based directed evolution platform, Adverum generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum has collaboration agreements with Regeneron Pharmaceuticals to research, develop, and commercialize gene therapy products for ophthalmic diseases and Editas Medicine to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. Adverum’s core capabilities include clinical development and in-house manufacturing expertise, specifically in process development and assay development. For more information please visit www.adverum.com.
Adverum Contact:
Leone Patterson
Chief Financial Officer
650-665-7222
[email protected]
